IELSG49Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)
Participants required:24 (enrolment completed)
Investigator responsible(s):A. Stathis, D. Rossi, E. Zucca
Objective(s):The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL.

Home | Go to Studies